Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of C-1311. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 17/20 | 0.98 |
| ▸ | SMARCA2 | P51531 | 2/20 | 0.89 |
| ▸ | NSD2 | O96028 | 1/20 | 0.89 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.84 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.84 |
| ▸ | NQO1 | P15559 | 2/20 | 0.82 |
| ▸ | MITF | O75030 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| C-1311 SCHEMBL29395834 | 1.00 | NQO2 (0.98) | NQO2SMARCA2NSD2KEAP1NFE2L2 | |
| C-1311 SCHEMBL31238169 | 0.99 | NQO2 (1.00) | NQO2SMARCA2NSD2KEAP1NFE2L2 | |
| C-1311 SCHEMBL2442405 | 0.99 | NQO2 (1.00) | NQO2SMARCA2NSD2KEAP1NFE2L2 | |
| SCHEMBL13526642 | 0.93 | NQO2 (1.00) | NQO2SMARCA2NSD2KEAP1NFE2L2 | |
| SCHEMBL13526627 | 0.90 | NQO2 (1.00) | NQO2SMARCA2NSD2KEAP1NFE2L2 | |
| SCHEMBL13526753 | 0.88 | NQO2 (0.80) | NQO2SMARCA2NSD2KEAP1NFE2L2 | |
| SCHEMBL13526716 | 0.88 | NQO2 (0.81) | NQO2SMARCA2NSD2KEAP1NFE2L2 | |
| SCHEMBL13526647 | 0.87 | NQO2 (0.84) | NQO2SMARCA2NSD2KEAP1NFE2L2 | |
| SCHEMBL13526758 | 0.87 | NQO2 (0.79) | NQO2SMARCA2NSD2KEAP1NFE2L2 | |
| Hydrochloric Acid SCHEMBL3379560 | 0.87 | NQO2 (0.98) | NQO2SMARCA2NSD2KEAP1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731220-A2 | METHODS OF TREATING CHRONIC LYMPHOCYTIC LEUKEMIA | Dana Farber Cancer Institute, Inc. (US) | 2026-04-29 | — | — | EP | claimed |
| WO-2024263861-A2 | METHODS OF TREATING CHRONIC LYMPHOCYTIC LEUKEMIA | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-12-26 | — | — | WO | claimed |
| CN-116510907-A | Phosphogypsum synchronous flotation impurity removal process | 宜都兴发化工有限公司 | 2023-08-01 | — | — | CN | claimed |
| CN-115532424-A | Phosphogypsum purification treatment process | 宜都兴发化工有限公司 | 2022-12-30 | — | — | CN | claimed |
| EP-4731220-A2 | METHODS OF TREATING CHRONIC LYMPHOCYTIC LEUKEMIA | Dana Farber Cancer Institute, Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| EP-2841109-B1 | PRODRUGS OF HYDROXYL-COMPRISING DRUGS | ASCENDIS PHARMA AS (DK) | 2026-04-15 | — | — | EP | disclosed |
| WO-2024263861-A2 | METHODS OF TREATING CHRONIC LYMPHOCYTIC LEUKEMIA | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-12-26 | — | — | WO | disclosed |
| CN-118853534-A | Immortalized sheep testis suspension cell line for efficient propagation of viruses | 中国检验检疫科学研究院 | 2024-10-29 | — | — | CN | disclosed |
| CN-110675388-B | Weld joint image similarity comparison method | 沈阳派得林科技有限责任公司 | 2024-02-02 | — | — | CN | disclosed |
| CN-116510907-A | Phosphogypsum synchronous flotation impurity removal process | 宜都兴发化工有限公司 | 2023-08-01 | — | — | CN | disclosed |
| CN-115532424-A | Phosphogypsum purification treatment process | 宜都兴发化工有限公司 | 2022-12-30 | — | — | CN | disclosed |
| CN-115196637-A | Method for recovering silicon powder for thermal spraying silicon target from residual silicon target | 福建阿石创新材料股份有限公司 | 2022-10-18 | — | — | CN | disclosed |